Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.

Inoue Y, Suzuki H, Hibino H, Takaya A, Mikami K, Yamamoto K, Matsumoto H

DOI: 10.1002/brb3.2109
Published: 2021 May
Container: Brain and behavior
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/brb3.2109,
  title = {Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.},
  author = {Inoue Y and Suzuki H and Hibino H and Takaya A and Mikami K and Yamamoto K and Matsumoto H},
  year = {2021},
  journal = {Brain and behavior},
  doi = {10.1002/brb3.2109},
  url = {https://doi.org/10.1002/brb3.2109}
}

RIS

TY  - JOUR
TI  - Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.
AU  - Inoue Y
AU  - Suzuki H
AU  - Hibino H
AU  - Takaya A
AU  - Mikami K
AU  - Yamamoto K
AU  - Matsumoto H
PY  - 2021
JO  - Brain and behavior
DO  - 10.1002/brb3.2109
UR  - https://doi.org/10.1002/brb3.2109
ER  -

APA

Y, I., H, S., H, H., A, T., K, M., K, Y., & H, M. (2021). Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.. Brain and behavior. https://doi.org/10.1002/brb3.2109

Source records

pubmed · retrieved 2026-09-27T12:05:06.515Z